SecBot SecBot
8-K ·Filed Jul 9, 2026

TVTX

Travere Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed4mo ago SEC0001438533-26-000054
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine succession planning for a non-CEO/CFO role with an internal successor already in place. No trading implications; monitor the 10-K filing in February 2027 for any related financial disclosures.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$56.59
T+0 close · Jul 9, 2026 · via day close
Latest settled
+1.91%
T+60 · $57.67
Vs SPY
−0.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 10 $56.59entry
  2. T+1 · 4mo ago −0.53%α +0.24% · $56.29
  3. T+5 · 4mo ago −2.31%α −1.75% · $55.28
  4. T+20 · 3mo ago +8.36%α +5.93% · $61.32
  5. T+60 · 6w ago +1.91%α −0.72% · $57.67
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Travere Therapeutics announced the planned retirement of CAO Sandra Calvin after the filing of the 2026 10-K (expected February 2027), with VP Controller John Torell set to succeed her. The transition is orderly with an internal replacement already named, making this a routine personnel event with no material financial impact.

Key Facts

  • CAO Sandra Calvin intends to retire following the filing of the 2026 annual report (expected February 2027).
  • John Torell, CFA, CPA, currently VP Controller, is expected to succeed her as CAO and PAO.
  • Torell joined Travere in 2021 and has overseen accounting operations, financial reporting, SEC reporting, and internal controls.
  • The Board is expected to appoint Torell in advance of the Retirement Date to ensure an orderly transition.

Financial Impact

No financial impact from this executive transition.

Risk Factors

  • Potential disruption if the transition timeline shifts or if Torell declines the appointment, though the filing indicates a clear plan.
  • No other risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001438533-26-000054
Document: 0001438533-26-000054-index-headers.html0001438533-26-000054
Document: 0001438533-26-000054-index.html0001438533-26-000054
Document: 0001438533-26-000054.txt0001438533-26-000054

Track record

21 reports on TVTX

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 10 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
  5. Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
  6. Jul 9, 202618w ago 8-K Neutral 2/10 Viewing Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
  7. Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
  8. Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
  9. Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
  10. Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 9, 2026